Arvinas (ARVN) Competitors

Arvinas presently has a consensus price target of $14.17, suggesting a potential upside of 67.65%. Biohaven has a consensus price target of $18.69, suggesting a potential upside of 46.50%. Given Arvinas' higher possible upside, research analysts plainly believe Arvinas is more favorable than Biohaven.

In the previous week, Biohaven had 14 more articles in the media than Arvinas. MarketBeat recorded 20 mentions for Biohaven and 6 mentions for Arvinas. Biohaven's average media sentiment score of 0.30 beat Arvinas' score of 0.03 indicating that Biohaven is being referred to more favorably in the news media.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arvinas has a net margin of 2.94% compared to Biohaven's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Biohaven's return on equity.

Arvinas has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Arvinas has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

In the previous week, Pharvaris had 35 more articles in the media than Arvinas. MarketBeat recorded 41 mentions for Pharvaris and 6 mentions for Arvinas. Pharvaris' average media sentiment score of 0.56 beat Arvinas' score of 0.03 indicating that Pharvaris is being referred to more favorably in the news media.

95.2% of Arvinas shares are held by institutional investors. 7.3% of Arvinas shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arvinas has a net margin of 2.94% compared to Pharvaris' net margin of 0.00%. Arvinas' return on equity of 1.91% beat Pharvaris' return on equity.

Arvinas currently has a consensus price target of $14.17, indicating a potential upside of 67.65%. Pharvaris has a consensus price target of $59.50, indicating a potential upside of 56.50%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Pharvaris.

Arvinas has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, meaning that its share price is 333% less volatile than the broader market.

Arvinas has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Arvinas has a net margin of 2.94% compared to Mesoblast's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Mesoblast's return on equity.

Arvinas presently has a consensus target price of $14.17, suggesting a potential upside of 67.65%. Mesoblast has a consensus target price of $39.00, suggesting a potential upside of 151.94%. Given Mesoblast's higher probable upside, analysts plainly believe Mesoblast is more favorable than Arvinas.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arvinas has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

In the previous week, Arvinas had 5 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Arvinas and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.72 beat Arvinas' score of 0.03 indicating that Mesoblast is being referred to more favorably in the news media.

Mesoblast has lower revenue, but higher earnings than Arvinas. Mesoblast is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sarepta Therapeutics currently has a consensus price target of $25.69, suggesting a potential upside of 25.61%. Arvinas has a consensus price target of $14.17, suggesting a potential upside of 67.65%. Given Arvinas' stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than Sarepta Therapeutics.

In the previous week, Sarepta Therapeutics had 5 more articles in the media than Arvinas. MarketBeat recorded 11 mentions for Sarepta Therapeutics and 6 mentions for Arvinas. Sarepta Therapeutics' average media sentiment score of 0.66 beat Arvinas' score of 0.03 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Arvinas has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Sarepta Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Arvinas has a net margin of 2.94% compared to Sarepta Therapeutics' net margin of -13.48%. Arvinas' return on equity of 1.91% beat Sarepta Therapeutics' return on equity.